Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24

Protara Therapeutics, Inc.

2023-Q3 EPS reported -$2.67

Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.
Cash, cash equivalents & investments of $74.0M as of Sept 30, expected to fund ops into Q2 2025.
R&D expenses rose to $6.2M from $3.5M, driven by TARA-002 clinical trial activities.
First patient dosed in Phase 2 ADVANCED-2 (NMIBC) and Phase 2 STARBORN-1 (lymphatic malformations) trials.
Preliminary results from ADVANCED-1EXP expansion trial in NMIBC on track for 1H24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protara Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $9.9 million, EPS $0.87 per share.

Period: the third quarter ended September 30, 2023
Net income: net loss of $9.9 million
EPS: $0.87 per share
Result: reported results

Exact text from the filing

For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-083011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.